We are live on ! Find out more
VYGR icon

Voyager Therapeutics
VYGR

125 hedge funds and large institutions have $569M invested in Voyager Therapeutics in 2018 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 49 increasing their positions, 29 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

180% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 10

69% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 29

58% more call options, than puts

Call options by funds: $1.08M | Put options by funds: $683K

16% more funds holding

Funds holding: 108 → 125 (+17)

12% more capital invested

Capital invested by funds: $509M → $569M (+$60.1M)

6.01% more ownership

Funds ownership: 84.03% → 90.04% (+6%)

Holders
125
Holders Change
+17
Holders Change %
+15.74%
% of All Funds
2.86%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.07%
New
28
Increased
49
Reduced
29
Closed
10
Calls
$1.08M
Puts
$683K
Net Calls
+$397K
Net Calls Change
+$1.06M

Top Buyers

Rank Fund Capital Flow
1
HCM
Highline Capital Management
New York
+$16.6M
2
GPP
Great Point Partners
Connecticut
+$14.4M
3
BB
BB Biotech
Switzerland
+$10.7M
4
AC
Armistice Capital
New York
+$8.54M
5
State Street
State Street
Massachusetts
+$8.52M

Top Sellers

Rank Fund Capital Flow
1
TGI
TRV GP III
Massachusetts
-$29.6M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$10.7M
3
Axa
Axa
France
-$4.75M
4
Deutsche Bank
Deutsche Bank
Germany
-$2.74M
5
FCM
Farallon Capital Management
California
-$2.41M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Investments
26
Two Sigma Investments
New York
$3.34M +$3.04M +153,717 +899%
Goldman Sachs
27
Goldman Sachs
New York
$3.25M +$2.3M +116,584 +233%
FT
28
Fiduciary Trust
Massachusetts
$3.02M +$15.3K +772 +0.5%
PP
29
PDT Partners
New York
$2.33M -$575K -29,100 -20%
DM
30
Deerfield Management
New York
$2.3M – – –
Charles Schwab
31
Charles Schwab
California
$1.99M +$293K +14,849 +17%
Two Sigma Advisers
32
Two Sigma Advisers
New York
$1.9M +$1.72M +86,900 +828%
Renaissance Technologies
33
Renaissance Technologies
New York
$1.87M -$2.29M -115,965 -55%
Prudential Financial
34
Prudential Financial
New Jersey
$1.76M +$1.78M +90,010 New
Bank of New York Mellon
35
Bank of New York Mellon
New York
$1.64M +$3.38K +171 +0.2%
3C
36
361 Capital
Colorado
$1.62M +$1.64M +83,006 New
TCIM
37
TIAA CREF Investment Management
New York
$1.59M +$884K +44,703 +123%
Victory Capital Management
38
Victory Capital Management
Texas
$1.52M -$85.4K -4,320 -5%
AWM
39
Aevitas Wealth Management
Massachusetts
$1.43M – – –
BCM
40
Bridgeway Capital Management
Texas
$1.37M – – –
Allianz Asset Management
41
Allianz Asset Management
Germany
$1.36M +$1.37M +69,448 New
AAMU
42
Amundi Asset Management US
Massachusetts
$1.27M +$1.28M +64,800 New
PFGIA
43
Patriot Financial Group Insurance Agency
Massachusetts
$1.26M +$223K +11,307 +21%
SCA
44
Secor Capital Advisors
New York
$1.02M +$209K +10,597 +25%
Deutsche Bank
45
Deutsche Bank
Germany
$1M -$2.74M -138,793 -73%
AA
46
ALPS Advisors
Colorado
$916K +$927K +46,900 New
TA
47
Teachers Advisors
New York
$896K +$98.3K +4,972 +12%
Citigroup
48
Citigroup
New York
$870K +$175K +8,845 +25%
Dimensional Fund Advisors
49
Dimensional Fund Advisors
Texas
$780K -$821K -41,553 -51%
VEA
50
Virtus ETF Advisers
New York
$733K -$314K -15,905 -30%
1
2
3 4 5

VYGR Hedge Fund Activity: Q2 2018 in Review

125 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Voyager Therapeutics (VYGR) for Q2 2018, worth a combined $569M — up 12% from $509M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new VYGR positions and 10 closed out — a net gain of 18 holders — while 49 added to existing stakes and 29 trimmed.

The largest buyer was Highline Capital Management, opening a new position worth an estimated $16.6M. The largest seller was TRV GP III, cutting an estimated $29.6M.

  • 125 institutional investors held Voyager Therapeutics (VYGR) as of Q2 2018, up from 108 in Q1 2018.
  • Funds reported $569M of Voyager Therapeutics stock for Q2 2018, up 12% quarter-over-quarter.
  • 28 funds opened new Voyager Therapeutics positions in Q2 2018 and 10 closed out, a net change of +18 holders.
  • The largest Voyager Therapeutics buyer in Q2 2018 was Highline Capital Management, an estimated $16.6M added.
  • The largest Voyager Therapeutics seller in Q2 2018 was TRV GP III, an estimated $29.6M sold.

Based on aggregated 13F filings for Q2 2018.